New Roads Leading to Ca 2+ Sensitization
2002; Lippincott Williams & Wilkins; Volume: 91; Issue: 2 Linguagem: Inglês
10.1161/01.res.0000028341.63905.91
ISSN1524-4571
Autores Tópico(s)Neurobiology and Insect Physiology Research
ResumoHomeCirculation ResearchVol. 91, No. 2New Roads Leading to Ca2+ Sensitization Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBNew Roads Leading to Ca2+ Sensitization Avril V. Somlyo Avril V. SomlyoAvril V. Somlyo From the Department of Molecular Physiology and Biological Physics, Department of Pathology, University of Virginia, Charlottesville, Va. Originally published26 Jul 2002https://doi.org/10.1161/01.RES.0000028341.63905.91Circulation Research. 2002;91:83–84Gprotein–coupled receptors (GPCRs) activated by a wide variety of agonists can switch on myosin light chain phosphorylation and force in smooth muscle. The extent of myosin light chain phosphorylation reflects activity of both the Ca2+/calmodulin–dependent myosin light chain kinase (MLCK) and the myosin light chain phosphatase. Thus, at constant Ca2+ and MLCK activity, processes that inhibit myosin phosphatase activity cause a leftward shift of the Ca2+ force-response curve, a physiological relevant phenomenon known as Ca2+ sensitization.1,2 There are two well-described myosin phosphatase inhibitory pathways. The first is through the small GTPase RhoA, in which GTP-bound RhoA translocates to the membrane and activates Rho-kinase that either directly or indirectly acts on the regulatory phosphatase subunit (MYPT-1) to inhibit phosphatase activity. The second signaling pathway, which is present in only some smooth muscles, is through phosphorylation of a phosphatase inhibitor, CPI-17 that, when phosphorylated, potently inhibits the catalytic subunit of myosin phosphatase.3 Crosstalk between the two pathways has been implicated from experiments using the Rho-kinase inhibitor Y-27632.4 A new signaling messenger of Ca2+ sensitization, which converges on the RhoA pathway at the level of Rho-kinase, is presented by Kobayashi and colleagues5 in this issue of Circulation Research: they demonstrate that sphingosylphosphorylcholine (SPC), a product of sphingomyelin deacylation, leads to an increase in force in the absence of an increase in the fura 2 Ca2+ signal. This force is inhibited by a Rho-kinase inhibitor, but not by inhibition of conventional or novel PKCs. Interestingly, the Ca2+-independent contraction was maintained for ≈2 hours, even after removal of SPC from the bathing medium, and was completely and reversibly relaxed by Y-27632: subsequent stimulation with 118 mmol/L K+ induced a normal increase in [Ca2+] and contraction. The redevelopment of force after a quick-release step during the maintained contraction indicated that SPC did not interfere with the ability of myosin crossbridges to hydrolyze MgATP and cycle normally. Provided that SPC is indeed released into the subarachnoid space, this study, carried out on cerebral arteries, has important implications for the therapy of cerebral vasospasm, a major health risk in some populations. Further studies on SPC production, regulation, and misregulation should establish its significance in normal and/or pathological states.Apart from their metabolic roles, lysophospholipids such as lysophosphatidic acid (LPA), sphingosine 1-phosphate (S1P), and sphingosylphosphorylcholine have long been known to be associated with cell growth and differentiation but are now also recognized as important signaling molecules functioning in a variety of intracellular pathways that target cell migration, cell growth, and cell survival (antiapoptosis), through effects on such processes as calcium mobilization, inhibition of adenylate cyclase, and activation of mitogen-activated protein kinases.6–9 S1P has also been implicated in cerebral vasospasm.10 It has been suggested6 that lysophospholipids are likely to be as important a class of intracellular signaling molecules as the glycerophospholipid metabolites, which give rise to inositol 1,4,5-trisphosphate (InsP3), diacylglycerol, phosphatidic acid, and arachidonic acid.A major advance in this still young field has been the identification and cloning of GPCRs for some of the lysophospholipids. Five of the eight GPCRs, commonly called Edg receptors for endothelial differentiation gene, bind S1P with nanomolar affinities and SPC ≈10- to 100-fold less efficiently. The remaining three receptors preferentially bind LPA. (For a review of current nomenclature and structure activity relationships of lysophospholipid messengers, see References 9 and 11.) SPC is reported to be a high-affinity ligand (KD=33 nmol/L) for the ovarian cancer G protein–coupled receptor 1 (OGR1); it is expressed in several tissues and upon activation leads to Ca2+ mobilization and activation of p42/44 mitogen-activated protein kinases.12 A second closely related GPCR, also claimed to be activated by SPC, GPR4, has also been identified.11 Surprisingly, SPC-mediated Ca2+ sensitization in the cerebral artery described in the present study5 does not appear to signal through a GPCR. This conclusion was largely based on the finding that, unlike agonist-induced Ca2+ sensitization, SPC does not require the addition of GTP to the permeabilized smooth muscles, nor was SPC-induced Ca2+ sensitization affected by the nonhydrolyzable GDPβS, which inhibits signaling by GPCRs. Some of these same investigators have also reported similar effects of SPC (1 to 50 μmol/L) on intact, denuded of endothelium, and permeabilized pig coronary artery smooth muscle.13 On the other hand, in intact endothelial cells, SPC and S1P increase cytoplasmic [Ca2+] through release of intracellular calcium as well as Ca2+ influx.14,15 SPC also increases production of NO, leading to endothelium-dependent vasorelaxation with an EC50=5 μmol/L.14 The different concentrations used by both groups make it probable that Ca2+ mobilization is through lysophospholipid GPCRs, whereas the activation of NO may be through direct action of SPC on the eNOS/NO pathway, because SPC readily crosses cell membranes. Evaluation of the contributions of SPC as a signaling molecule in vascular biology will require determination of the intracellular and extracellular concentrations of SPC in normal and pathological states.If SPC, as suggested, directly activates Rho-kinase, it may be that it interacts with the putative negative regulatory region of Rho-kinase, possibly the pleckstrin homology domain (PH), based on consideration of the effects of arachidonic acid in vitro.16–18 In this model, the Rho binding domain (RB) and PH domains interact with the catalytic domain to inactivate the kinase (Figure). The enzyme is thought to be activated by the binding of RhoA · GTP to RB, thereby releasing the inhibition of the catalytic site. Perhaps SPC and other lipid messengers activate Rho-kinase through a similar mechanism, releasing the inhibitory from the catalytic domain through a conformational change and exposing the catalytic site. Direct activation of Rho-kinase by lipid messengers should not be inhibited by upstream inactivation of RhoA by the bacterial exoenzyme C3, whereas an inhibitor of SPC production (eg, sphingomyelin deacylation) would be expected to inhibit vasospasm due to subarachnoid hemorrhage.19 These experiments remain to be performed. Download figureDownload PowerPointSimplified scheme of the RhoA signaling pathway leading to Ca2+ sensitization. Agonist activation of GPCRs, through yet to identified Rho · GTP exchange factor(s), leads to exchange of GTP for GDP on and activation of RhoA, which in turn activates Rho-kinase. The C-terminal putative negative regulatory domain of Rho-kinase includes a pleckstrin homology domain (PH) and a Rho binding domain (RB) and is thought to interact and inactivate the catalytic domain. Binding of RhoA · GTP to RB results in a conformational change and exposure of the active catalytic subunit.16 Rho-kinase, either directly or indirectly, possibly through other kinases such as ZIP-like kinase20 or integrin-linked kinase,21,22 ultimately leads to inhibition of myosin light chain phosphatase resulting in an increase in myosin light chain phosphorylation and in force, independently of a change in cytosolic Ca2+. Now sphingosylphosphorylcholine, SPC, like arachidonic acid, AA, is suggested to directly activate Rho kinase.5In summary, these and other studies revealing the activities of intracellular and extracellular phospholipid mediators point to new mechanisms of signaling and potential new therapeutic targets for pathophysiological states of the cardiovascular system.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Avril V. Somlyo, Department of Molecular Physiology and Biological Physics, University of Virginia, PO Box 800736, Jordan Hall, Charlottesville, VA 22908-0736. E-mail [email protected] References 1 Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000; 522(pt 2): 177–185.MedlineGoogle Scholar2 Solaro RJ. Myosin light chain phosphatase: a Cinderella of cellular signaling. Circ Res. 2000; 87: 173–175.CrossrefMedlineGoogle Scholar3 Eto M, Ohmori T, Suzuki M, Furuya K, Morita F. A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C: isolation from porcine aorta media and characterization. J Biochem. 1995; 118: 1104–1107.CrossrefMedlineGoogle Scholar4 Kitazawa T, Eto M, Woodsome TP, Brautigan DL. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem. 2000; 275: 9897–9900.CrossrefMedlineGoogle Scholar5 Shirao S, Kashiwagi S, Sato M, Miwa S, Nakao F, Kurokawa T, Todoroki-Ikeda N, Mogami K, Mizukami Y, Kuriyama S, Haze K, Suzuki M, Kobayashi S. Sphingosylphosphorylcholine is a novel messenger for Rho-kinase–mediated Ca2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circ Res. 2002; 91: 112–119.LinkGoogle Scholar6 Spiegel S, Milstein S. Sphingolipid metabolites: members of a new class of lipid second messengers. J Membr Biol. 1995; 146: 225–237.MedlineGoogle Scholar7 Fukushima N, Ishii I, Contos JJA, Weiner JA, Chun J. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol. 2001; 41: 507–534.CrossrefMedlineGoogle Scholar8 Sekiguchi K, Yokoyama T, Kurabayashi M, Okajima F, Nagai R. Sphingosylphosphorylcholine induces a hypertrophic growth response through the mitogen-activated protein kinase signaling cascade in rat neonatal cardiac myocytes. Circ Res. 1999; 85: 1000–1008.CrossrefMedlineGoogle Scholar9 Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S, Tigyi G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2002; 54: 265–269.CrossrefMedlineGoogle Scholar10 Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, Kimura T, Sasaki T. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke. 2001; 32: 2913–2919.CrossrefMedlineGoogle Scholar11 Lynch K, MacDonald TL. Structure activity relationships of lysophospholipid mediators. Prostaglandins. 2001; 64: 33–45.CrossrefGoogle Scholar12 Xu Y, Zhu K, Hong G, Wu W, Baudhuin LM, Xiao Y, Damron DS. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol. 2000; 2: 261–267.CrossrefMedlineGoogle Scholar13 Todoroki-Ikeda N, Mizukami Y, Mogami K, Kusuda T, Yamamoto K, Miyake T, Sato M, Suzuki S, Yamagata H, Hokazono Y, Kobayashi S. Sphingosylphosphorylcholine induces Ca2+-sensitization of vascular smooth muscle contraction: possible involvement of Rho-kinase. FEBS Lett. 2000; 483: 85–90.CrossrefGoogle Scholar14 Mogami K, Mizukami Y, Todoroki-Ikeda N, Ohmura M, Yoshida K, Miwa S, Matsuzaki M, Matsuda M, Kobayashi S. Sphingosylphosphorylcholine induces cytosolic Ca2+ elevation in endothelial cells in situ and causes endothelium-dependent relaxation through nitric oxide production in bovine coronary artery. FEBS Lett. 1999; 457: 375–380.CrossrefMedlineGoogle Scholar15 Meyer ZU, Heringdorf D, van Koppen CJ, Windorfer B, Himmel HM, Jakobs KH. Calcium signaling by G protein-coupled sphingolipid receptors in bovine aortic endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1996; 354: 397–403.CrossrefMedlineGoogle Scholar16 Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res. 2000; 261: 44–51.CrossrefMedlineGoogle Scholar17 Fu X, Gong MC, Jia T, Somlyo AV, Somlyo AP. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPγS-, and phorbol ester-induced Ca2+-sensitization of smooth muscle. FEBS Lett. 1998; 440: 183–187.CrossrefMedlineGoogle Scholar18 Araki S, Ito M, Kureishi Y, Feng J, Machida H, Isaka N, Amano M, Kaibuchi K, Hartshorne DJ, Nakano T. Arachidonic acid-induced Ca2+ sensitization of smooth muscle contraction through activation of Rho-kinase. Pflugers Arch. 2001; 441: 596–603.CrossrefMedlineGoogle Scholar19 Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of Rho-kinase mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000; 87: 195–200.CrossrefMedlineGoogle Scholar20 MacDonald JA, Borman MA, Muranyi A, Somlyo AV, Hartshorne DJ, Haystead TA. Identification of the endogenous smooth muscle myosin phosphatase-associated kinase. Proc Natl Acad Sci U S A. 2001; 98: 2419–2424.CrossrefMedlineGoogle Scholar21 Deng JT, Van Lierop JE, Sutherland C, Walsh MP. Ca2+-independent smooth muscle contraction: a novel function for integrin-linked kinase. J Biol Chem. 2001; 276: 16365–16373.CrossrefMedlineGoogle Scholar22 Muranyi A, MacDonald JA, Deng JT, Wilson DP, Haystead TA, Walsh MP, Erdodi F, Kiss E, Wu Y, Hartshorne DJ. Phosphorylation of the myosin phosphatase target subunit by integrin-linked kinase. Biochem J. May 27, 2002; 10.1042/BJ20020401. Available at: http://www.biochemj.org. Accessed June 24, 2002.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Vaziri N, Moradi H and Zhao Y (2022) Altered lipid metabolism and serum lipids in chronic kidney disease Nutritional Management of Renal Disease, 10.1016/B978-0-12-818540-7.00009-4, (43-60), . Ge D, Yue H, Liu H and Zhao J (2018) Emerging roles of sphingosylphosphorylcholine in modulating cardiovascular functions and diseases, Acta Pharmacologica Sinica, 10.1038/s41401-018-0036-4, 39:12, (1830-1836), Online publication date: 1-Dec-2018. Anjum I, Denizalti M, Kandilci H, Durlu-Kandilci N and Sahin-Erdemli I (2017) Enhancement of S1P-induced contractile response in detrusor smooth muscle of rats having cystitis, European Journal of Pharmacology, 10.1016/j.ejphar.2017.08.043, 814, (343-351), Online publication date: 1-Nov-2017. Chen D, Lv B, Kobayashi S, Xiong Y, Sun P, Lin Y, Genovese S, Epifano F, Hou S, Tang F, Ji Y and Yu D (2016) Madagascine Induces Vasodilatation via Activation of AMPK, Frontiers in Pharmacology, 10.3389/fphar.2016.00435, 7 Dobiaš L, Laššánová M and Kristová V (2016) Hypolipidemic drugs and their effect on endothelial function: a review of results of clinical trials, Klinická farmakologie a farmacie, 10.36290/far.2016.018, 30:2, (38-45), Online publication date: 19-Sep-2016. Durlu-Kandilci N, Denizalti M and Sahin-Erdemli I (2015) Aging changes agonist induced contractile responses in permeabilized rat bladder, AGE, 10.1007/s11357-015-9807-8, 37:4, Online publication date: 1-Aug-2015. Vaziri N (2013) Altered Lipid Metabolism and Serum Lipids in Kidney Disease and Kidney Failure Nutritional Management of Renal Disease, 10.1016/B978-0-12-391934-2.00003-5, (31-48), . Claudino M and Fertrin K (2012) Sickling Cells, Cyclic Nucleotides, and Protein Kinases: The Pathophysiology of Urogenital Disorders in Sickle Cell Anemia, Anemia, 10.1155/2012/723520, 2012, (1-13), . Bivalacqua T, Musicki B, Kutlu O and Burnett A (2012) New Insights into the Pathophysiology of Sickle Cell Disease‐Associated Priapism, The Journal of Sexual Medicine, 10.1111/j.1743-6109.2011.02288.x, 9:1, (79-87), Online publication date: 1-Jan-2012. Laughlin M, Davis M, Secher N, Lieshout J, Arce‐Esquivel A, Simmons G, Bender S, Padilla J, Bache R, Merkus D and Duncker D (2012) Peripheral Circulation Comprehensive Physiology, 10.1002/cphy.c100048, (321-447) Sathish V, Yang B, Meuchel L, VanOosten S, Ryu A, Thompson M, Prakash Y and Pabelick C (2011) Caveolin-1 and force regulation in porcine airway smooth muscle, American Journal of Physiology-Lung Cellular and Molecular Physiology, 10.1152/ajplung.00322.2010, 300:6, (L920-L929), Online publication date: 1-Jun-2011. Denizalti M, Durlu-Kandilci N, Bozkurt T and Sahin-Erdemli I (2011) Hydrogen sulphide inhibits carbachol-induced contractile responses in β-escin permeabilized guinea-pig taenia caecum, European Journal of Pharmacology, 10.1016/j.ejphar.2011.02.017, 658:2-3, (229-235), Online publication date: 1-May-2011. Papadopoulos G, Delakas D, Nakopoulou L and Kassimatis T (2011) Statins and prostate cancer: Molecular and clinical aspects, European Journal of Cancer, 10.1016/j.ejca.2011.01.005, 47:6, (819-830), Online publication date: 1-Apr-2011. Minshall R, Vandenbroucke E, Holinstat M, Place A, Tiruppathi C, Vogel S, van Nieuw Amerongen G, Mehta D and Malik A (2010) Role of protein kinase Cζ in thrombin-induced RhoA activation and inter-endothelial gap formation of human dermal microvessel endothelial cell monolayers, Microvascular Research, 10.1016/j.mvr.2010.04.007, 80:2, (240-249), Online publication date: 1-Sep-2010. Kassimatis T and Konstantinopoulos P (2009) The role of statins in chronic kidney disease (CKD): Friend or foe?, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2009.03.008, 122:3, (312-323), Online publication date: 1-Jun-2009. Tran C, Vigmond E, Plane F and Welsh D (2009) Mechanistic basis of differential conduction in skeletal muscle arteries, The Journal of Physiology, 10.1113/jphysiol.2008.166017, 587:6, (1301-1318), Online publication date: 15-Mar-2009. Kawamichi H, Kishi H, Kajiya K, Takada Y and Kobayashi S (2009) Molecular mechanisms of abnormal vascular contraction and the screening for their molecular-targeted therapeutic drugs, Folia Pharmacologica Japonica, 10.1254/fpj.133.124, 133:3, (124-129), . Durlu-Kandilci N and Sahin-Erdemli I (2008) The effects of reactive oxygen species on calcium- and carbachol- induced contractile responses in β-escin permeabilized rat bladder, Naunyn-Schmiedeberg's Archives of Pharmacology, 10.1007/s00210-008-0326-3, 378:6, (645-653), Online publication date: 1-Dec-2008. Kim H, Kim H, Han E, Park S, Koh J, Kim K, Noh M, Kim J and Lee C (2008) Characterizations of sphingosylphosphorylcholine-induced scratching responses in ICR mice using naltrexon, capsaicin, ketotifen and Y-27632, European Journal of Pharmacology, 10.1016/j.ejphar.2008.01.005, 583:1, (92-96), Online publication date: 1-Mar-2008. Hashiba Y, Tosaka M, Saito N, Imai H, Shimizu T and Sasaki T (2013) Vasorelaxing effect of the Rho-kinase inhibitor, Y-27632, in isolated canine basilar arteries, Neurological Research, 10.1179/016164107X164076, 29:5, (485-489), Online publication date: 1-Jul-2007. Lartey J, Smith M, Pawade J, Strachan B, Mellor H and Bernal A (2007) Up-Regulation of Myometrial RHO Effector Proteins (PKN1 and DIAPH1) and CPI-17 (PPP1R14A) Phosphorylation in Human Pregnancy Is Associated with Increased GTP-RHOA in Spontaneous Preterm Labor1, Biology of Reproduction, 10.1095/biolreprod.106.058982, 76:6, (971-982), Online publication date: 1-Jun-2007. Gerthoffer W (2007) Mechanisms of Vascular Smooth Muscle Cell Migration, Circulation Research, 100:5, (607-621), Online publication date: 16-Mar-2007. Kishi H, Kawamichi H, Kajiya K and Kobayashi S (2007) The involvement of Fyn tyrosine kinase and membrane rafts in the signal transduction in Ca2+-sensitization of vascular smooth muscle contraction, Folia Pharmacologica Japonica, 10.1254/fpj.129.245, 129:4, (245-251), . Lartey J, Gampel A, Pawade J, Mellor H and Bernal A (2006) Expression of RND Proteins in Human Myometrium1, Biology of Reproduction, 10.1095/biolreprod.105.049130, 75:3, (452-461), Online publication date: 1-Sep-2006. Morikage N, Kishi H, Sato M, Guo F, Shirao S, Yano T, Soma M, Hamano K, Esato K and Kobayashi S (2006) Cholesterol Primes Vascular Smooth Muscle to Induce Ca2 Sensitization Mediated by a Sphingosylphosphorylcholine–Rho-Kinase Pathway, Circulation Research, 99:3, (299-306), Online publication date: 4-Aug-2006. Gonscherowski V, Becker B, Moroder L, Motrescu E, Gil-Parrado S, Gloe T, Keller M and Zahler S (2006) Calpains: a physiological regulator of the endothelial barrier?, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00772.2004, 290:5, (H2035-H2042), Online publication date: 1-May-2006. Haystead T (2005) ZIP kinase, a key regulator of myosin protein phosphatase 1, Cellular Signalling, 10.1016/j.cellsig.2005.05.008, 17:11, (1313-1322), Online publication date: 1-Nov-2005. Hu E and Lee D (2005) Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges, Expert Opinion on Therapeutic Targets, 10.1517/14728222.9.4.715, 9:4, (715-736), Online publication date: 1-Aug-2005. Brandes R (2005) Statin-Mediated Inhibition of Rho, Circulation Research, 96:9, (927-929), Online publication date: 13-May-2005. REN J and FANG C (2005) Small guanine nucleotide-binding protein Rho and myocardial function, Acta Pharmacologica Sinica, 10.1111/j.1745-7254.2005.00059.x, 26:3, (279-285), Online publication date: 1-Mar-2005. Hayashi A, Ohnishi H, Okazawa H, Nakazawa S, Ikeda H, Motegi S, Aoki N, Kimura S, Mikuni M and Matozaki T (2004) Positive Regulation of Phagocytosis by SIRPβ and Its Signaling Mechanism in Macrophages, Journal of Biological Chemistry, 10.1074/jbc.M400950200, 279:28, (29450-29460), Online publication date: 1-Jul-2004. Saba J and Hla T (2004) Point-Counterpoint of Sphingosine 1-Phosphate Metabolism, Circulation Research, 94:6, (724-734), Online publication date: 2-Apr-2004.Kanaide H, Ichiki T, Nishimura J and Hirano K (2003) Cellular Mechanism of Vasoconstriction Induced by Angiotensin II, Circulation Research, 93:11, (1015-1017), Online publication date: 28-Nov-2003. SOMLYO A and SOMLYO A (2003) Ca 2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase , Physiological Reviews, 10.1152/physrev.00023.2003, 83:4, (1325-1358), Online publication date: 1-Oct-2003. Shum W, Le G, Jones R, Gurney A and Sasaki Y (2009) Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP 3 receptor agonists , British Journal of Pharmacology, 10.1038/sj.bjp.0705393, 139:8, (1449-1461), Online publication date: 1-Aug-2003. Nakao F, Kobayashi S, Mogami K, Mizukami Y, Shirao S, Miwa S, Todoroki-Ikeda N, Ito M and Matsuzaki M (2002) Involvement of Src Family Protein Tyrosine Kinases in Ca2+ Sensitization of Coronary Artery Contraction Mediated by a Sphingosylphosphorylcholine-Rho-Kinase Pathway, Circulation Research, 91:10, (953-960), Online publication date: 15-Nov-2002. July 26, 2002Vol 91, Issue 2 Advertisement Article InformationMetrics https://doi.org/10.1161/01.RES.0000028341.63905.91PMID: 12142337 Originally publishedJuly 26, 2002 Keywordsmyosin phosphatasevasospasmsphingolipidsRho-kinasesmooth musclePDF download Advertisement
Referência(s)